PRDS — Pardes Biosciences Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall Cap
- $133.95m
- -$19.25m
U.S. STOCKS ON THE MOVE-Argenx, ViewRay, Ford
Pardes Biosciences up on buyout deal with MediPacific
U.S. STOCKS ON THE MOVE-Activision Blizzard, Tesla, Paramount Global
Pardes Biosciences gains on buyout deal with MediPacific
Brief: Pardes Biosciences Enters Into Agreement To Be Acquired By Medipacific For Between $2.02 & $2.19 In Cash Per Share Plus Contingent Value Rights
Brief: Pardes Biosciences Reports First Quarter 2023 Financial Results
Brief: Pardes Biosciences posts Q1 basic EPS of USD -0.3
Brief: Pardes Biosciences And Brian P. Kearney Agreed That Kearney's Employment Will Terminate
Brief: James Tananbaum Submitted To Board Of Pardes Biosciences Inc A Non-Binding Expression Of Interest Letter
U.S. RESEARCH ROUNDUP-Heska, Prudential Financial, ServiceNow
U.S. STOCKS ON THE MOVE-Baker Hughes, Cano Health, Ascendis
U.S. STOCKS ON THE MOVE- Lockheed Martin, Heska Corp, Teck Resources
Pardes Bio falls as COVID-19 drug fails mid-stage trial
Brief: Pardes Biosciences Inc Says Pomotrelvir Did Not Meet Primary Endpoint
Pardes Biosciences to suspend COVID-19 drug development after mid-stage trial fails (updated)
Pardes Biosciences to suspend COVID-19 drug development after mid-stage trial fails
Brief: Pardes Biosciences Reports Q4 And Full Year 2022 Financial Results And Provides Business Update
Brief: Pardes Biosciences Q4 loss per share $0.41
Brief: Pardes Biosciences Inc Files For Mixed Shelf Of Up To $200 Million- SEC Filing